Boston Scientific Receives CE Mark for Next Generation WATCHMAN FLX Stroke-Preventing Device

Boston Scientific WATCHMAN FLX

Patients with Atrial Fibrillation (Afib) are five times more likely to suffer a stroke than someone with a normal heart rhythm. In people with non-valvular Afib, data suggests that more than 90% of stroke-causing blood clots that come from the heart are formed in the left atrial appendage. Boston Scientific’s WATCHMAN left atrial appendage occlusion devices are intended to reduce the risk of stroke in people with non-valvular atrial fibrillation.  

Read more Cambridge Heartwear Announces Release of ‘Heartsense Monitor,’ the First AI-Driven Wearable Heart Monitor

The company just received European CE Mark for its next generation of the WATCHMAN FLX Left Atrial Appendage Closure (LAAC) device. Boston Scientific also initiated a limited market release of the device, reports Boston Scientific.

“The WATCHMAN device has been implanted in more than 75,000 patients worldwide and we are pleased that this next-generation technology has been granted European regulatory approval so that we can offer it to patients and clinicians throughout Europe,” said Kevin Ballinger, president, Interventional Cardiology, Boston Scientific. “The robust clinical evidence and successful commercial outcomes of the WATCHMAN device to-date reinforce the value of this procedure for all appropriate patients.”

Boston scientific

The technology is minimally invasive, and the new generation of WATCHMAN FLX was designed for simplified implantation to fit a wider range of patients, from those with simple to the most complex anatomies. The device allows for implantation flexibility to customize placement with a fully enclosed and rounded frame and by offering physicians the ability to fully recapture and reposition the device during the procedure. Furthermore, the frame of the new device is designed to enhance sealing within the left atrial appendage.

Read more Abbott’s HeartMate 3 Heart Pump for Advanced Heart Failure Patients Gets FDA Approval

Boston Scientific has started a limited market release of the device in Europe and expects to expand commercialization to additional sites in the second half of 2019. The company also plans to begin enrolling European patients in a post-approval registry in the coming months.

In the U.S., the WATCHMAN FLX device is an investigational device and not available for sale.